News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nordion International Sells Targeted Therapy Biz for $200 Million



7/17/2013 10:33:41 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Canada-based Nordion sheds its targeted therapy business and the TheraSphere targeted liver cancer therapy to BTG plc for $200 million. Ottawa-based Nordion (NYSE:NDZ) unloaded its targeted therapy business, handing the division, related products and about 40 employees over to British life sciences company BTG plc for $200 million. BTG will take over the division's lone product, an increasingly lucrative targeted liver cancer therapy system called TheraSphere. TheraSphere has driven strong recent growth, generating $48.5 million in revenues in 2012, a 14% bump over 2011 figures, according to the Ottawa Business Journal.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES